Drug Trial News

RSS

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

MicroDose Therapeutx Inc. today announced that its collaborators at the University of Pittsburgh (Pitt) have completed a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI).

8 Jun 2011

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.

8 Jun 2011

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Cipher Pharmaceuticals Inc. today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin for the treatment of severe, nodular acne.

8 Jun 2011

$Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS$

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik, Inc. today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome.

8 Jun 2011

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

7 Jun 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

7 Jun 2011

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.

7 Jun 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

7 Jun 2011

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Results from the DACO-016 trial of Dacogen (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Independent investigators reported today full results from the NEO3-09 study, reaffirming earlier top-line results that showed Lymphoseek met all primary and secondary endpoints and exhibited superior performance to vital blue dye in intraoperative lymphatic mapping (ILM) procedures.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

7 Jun 2011

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

Sound Pharmaceuticals (SPI) will begin recruiting a new clinical trial testing the oral drug SPI-1005 to prevent the hearing loss induced by loud music. Exposure to loud music or noise can induce temporary and permanent auditory threshold shifts (TTS or PTS). In some people, a repeated TTS will ultimately give way to a PTS that is irreversible.

7 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Drug Trial News

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Unique clinical trial addresses important questions about treating AIDS-related cancers

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News